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Abstract: Lopinavir/ritonavir is the ﬁ  rst and only coformulated HIV-1 protease inhibitor 
(PI). Large clinical trials have demonstrated lopinavir/ritonavir’s clinical efﬁ  cacy in both 
antiretroviral-naïve and -experienced patients. The immunologic and virologic beneﬁ  ts of 
treatment with this agent have been proven in HIV-infected adults, adolescents, and children. 
Smaller studies support the use of lopinavir/ritonavir monotherapy as a therapeutic option in 
certain patients. The drug is characterized by a high genetic barrier to resistance, and appears to 
be more forgiving of non-adherence than earlier, unboosted PIs. The most frequent side effects 
observed are diarrhea, nausea, and vomiting. These gastrointestinal adverse effects are generally 
mild to moderate. Metabolic derangements, including hyperlipidemia and glucose intolerance, 
have also been observed in lopinavir/ritonavir recipients. As the menu of available antiretroviral 
agents continues to expand, lopinavir/ritonavir remains a proven and effective drug for the 
treatment of HIV infection.
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Highly active antiretroviral therapy (HAART) has revolutionized the management 
of HIV-1 infection. Antiretroviral therapy has improved steadily in terms of efﬁ  cacy, 
tolerability, and dosing convenience since the advent of HAART in 1995. Lopinavir/
ritonavir (Kaletra®) was the sixth drug in the HIV-1 protease inhibitor (PI) class to be 
approved by the US Food and Drug Administration (FDA). Approved in September 
2000 in the US (April 2001 in Europe) for the treatment of HIV infection in adults and 
children older than 6 months of age, it was the ﬁ  rst, and only, PI to be coformulated. 
It has been widely and effectively used in both antiretroviral naïve and experienced 
HIV-infected patients around the world. The current tablet formulation of lopinavir/
ritonavir was approved by the FDA in October 2005, and the capsule formulation 
was phased out in the US 6 months later in favor of the new tablet. This article will 
review the pharmacologic and clinical aspects of lopinavir/ritonavir in the manage-
ment of HIV infection.
Historical aspects
The availability of PIs changed the landscape of HIV therapy. Treatment with these 
agents produced virologic and immunologic improvements not previously seen with 
the nucleoside reverse transcriptase inhibitors (NRTIs) that were the standard of care 
(Sham et al 1998). They offered, for the ﬁ  rst time, the possibility of long-term survival 
to persons living with HIV/AIDS (PLWHAs) (Deeks et al 1997; Sham et al 1998; 
Rana and Dudley 1999). However, all of the early PIs had limited bioavailability, high 
protein binding, large pill burdens, and short half-lives producing low trough levels 
(ie, nadir drug levels at the end of a dosing interval) and requiring frequent dosing. 
They were also associated with signiﬁ  cant side effects that compromised adherence, Therapeutics and Clinical Risk Management 2008:4(5) 1024
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and thus promoted the development of drug resistance (Deeks 
et al 1997; Sham et al 1998). Virologic failure was extremely 
common in those who did not maintain very high levels of 
adherence (Paterson et al 2000), and the outlook for patients 
who failed their ﬁ  rst PI-based regimen was bleak (Gulick 
et al 2000; Hammer et al 2003).
In 1997, Abbott Laboratories unveiled its new protease 
inhibitor, ABT-378, later to be named lopinavir, at the 4th 
Conference on Retroviruses and Opportunistic Infections. 
It was developed in an attempt to retain activity despite 
mutations in the HIV-1 protease gene. Lopinavir was found 
to be 3 to 4 times more active against HIV than ritonavir. 
Administered alone, lopinavir exhibits poor bioavailability. 
However, its blood levels are dramatically increased by 
low doses of ritonavir, a potent inhibitor of cytochrome 
P450 3A4. Coformulated lopinavir/ritonavir was the ﬁ  rst 
combination pill to contain a drug (lopinavir) not available 
separately. Lopinavir/ritonavir (Kaletra®) received acceler-
ated FDA approval for the treatment of HIV infection in 
combination with other agents for both antiretroviral naïve 
and experienced patients. The approval was based upon 
analyses of plasma HIV RNA and CD4+ lymphocyte count 
outcomes in a controlled study of treatment of HIV infection 
with lopinavir/ritonavir and in smaller uncontrolled dose-
ranging studies of lopinavir/ritonavir of 72 weeks duration 
(FDA/Center for Drug Evaluation and Research). Lopinavir 
was not the ﬁ  rst PI to take advantage of ritonavir boosting, but 
the improved efﬁ  cacy of lopinavir/ritonavir over prior agents 
(Walmsley et al 2002) ushered in an era in which ritonavir 
boosting of PI therapy became the norm in HIV management. 
The original formulation of lopinavir/ritonavir (Kaletra®) was 
a soft-gelatin capsule containing 133.3 mg of lopinavir and 
33.3 mg of ritonavir, and it required storage in a refrigerator. 
The recommended adult dosage of the original formulation 
was 3 capsules taken twice daily (or 6 tablets once daily in 
antiretroviral-naïve patients). A new tablet formulation of 
lopinavir/ritonavir which used proprietary melt-extrusion 
technology (Meltrex™) was approved by the FDA in 2005. 
The new formulation consisted of a stable, solid dispersion 
of the drugs within a tablet. The new Kaletra® tablets each 
contain 200 mg lopinavir and 50 mg ritonavir. This formu-
lation provides a lower pill burden, similar bioavailability, 
decreased effect of food on absorption of the drug, and an 
elimination of the refrigeration requirement (Klein et al 
2007). In April 2005, the FDA issued an additional approval 
for once-daily lopinavir/ritonavir in adult patients with no 
prior antiretroviral treatment. An oral solution of lopinavir/
ritonavir containing 80 mg lopinavir and 20 mg ritonavir 
per ml is available and must be taken with food. Since 
2007 a lower-dose tablet formulation of lopinavir/ritonavir 
(100 mg/25 mg) has been available in the US (available in 
the EU since early 2008) for the pediatric population.
The introduction of lopinavir/ritonavir to the developing 
world has been accompanied by some controversy. Initia-
tives begun in recent years to make HAART available in 
resource poor areas have placed pressure on drug manufac-
turers to supply their medications at reduced cost. Current 
World Health Organization (WHO) guidelines recommend 
lopinavir/ritonavir, boosted fosamprenavir, or boosted 
atazanavir as the anchor drugs in second line regimens (World 
Health Organization 2006). WHO notes lopinavir/ritonavir’s 
co-formulation and heat stability as advantages over the 
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Figure 1 Molecular structures of lopinavir (ABT-378) and ritonavir (RTV). Courtesy of Abbott Laboratories, with permission.Therapeutics and Clinical Risk Management 2008:4(5) 1025
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other PIs. In the developing world, lopinavir/ritonavir tablets 
are distributed under the brand name, Aluvia, a formulation 
that is pharmacologically identical to but visually distinct 
from Kaletra®. Abbott Laboratories has been the target of 
criticism for not distributing the drug widely enough and 
for not making it affordable enough (Third World Network 
2006). As of April 2007, Abbott has offered lopinavir/rito-
navir through its preferential pricing program to all of Africa 
and some additional “least developed” nations at a price of 
US$500 annually per patient, and to 45 “lower income” 
and “lower middle income” nations at a price of US$1000 
annually per patient. The annual price is considerably higher 
than that of other anchor drugs, especially nevirapine, but is 
discounted more than 90% from the cost in the developed 
world. To date, the efforts of generic drug manufacturers to 
develop an equivalent product for a lower price have been 
unsuccessful.
Pharmacology
Pharmacokinetics
The standard adult dose of lopinavir/ritonavir is 400 mg/100 
mg twice daily. The mean peak plasma concentration (Cmax) 
at this dose is 9.8 ± 3.7 μg/mL, occurring approximately 4 
hours after administration of a dose. A once-daily dosing 
regimen of 800 mg/200 mg may be used in therapy-naïve 
patients. This regimen is not recommended for therapy 
experienced patients. The tablets should be swallowed 
whole, and should not be chewed, crushed, or broken. Food 
intake does not affect absorption of the tablet formulation. 
However, the liquid formulation should be taken with food 
to improve absorption. The absolute bioavailability of 
lopinavir co-formulated with ritonavir in humans has not 
been established. At steady state, lopinavir is approximately 
98%–99% bound to plasma proteins. The mean trough 
concentration is 5.2 μg/mL and the mean elimination half-
life of lopinavir/ritonavir ranges from 2 to 3 hours after 
a single dose and from 4 to 6 hours after multiple-dose 
administration. Lopinavir/ritonavir accumulates intracel-
lularly and the intracellular/plasma concentration ratio is 
1.18 (Crommentuyn et al 2004). Lopinavir is lipid-soluble 
and penetrates the cerebrospinal ﬂ  uid (CSF). It produces 
signiﬁ  cant reductions in the CSF viral load (Yilmaz et al 
2004; Letendre et al 2007). Lopinavir undergoes rapid 
ﬁ  rst-pass metabolism in the liver by CYP3A4 and CYP3A5. 
Ritonavir inhibits the CYP3A4 isoenzyme in the human 
liver microsomes and results in increased concentrations of 
lopinavir when the two drugs are coadministered (Kumar 
et al 1999). Lopinavir/ritonavir is primarily eliminated by 
the fecal route with urinary excretion accounting for  2% 
of the eliminated drug (Kumar et al 2004).
Mechanism of action
HIV-1 protease is an aspartic protease that cleaves both 
structural and functional proteins from precursor viral 
polypeptide strands and fulﬁ  lls an essential role in the viral 
lifecycle. Inhibition of the protease produces immature, 
non-infectious virions. Lopinavir is a potent inhibitor of 
HIV-1 protease. The lopinavir/ritonavir coformulation 
produces its antiviral effect by inhibiting the formation of 
infectious virions, thus preventing subsequent waves of 
cellular infection (Flexner 1998).
Use in pregnancy
Lopinavir/ritonavir is classiﬁ  ed as category C (ie, no adequate 
and well-controlled studies in pregnant women – should be 
used only if the potential beneﬁ  t justiﬁ  es the potential risk 
to the fetus) for use in pregnant women. There are no con-
trolled studies evaluating the use of lopinavir/ritonavir in 
pregnant women with HIV infection. No treatment-related 
malformations were observed when lopinavir in combination 
with ritonavir was administered to pregnant rats or rabbits. 
Developmental anomalies in embryos and fetuses were 
observed when rats were treated with supratherapeutic doses 
of lopinavir/ritonavir (Cunha et al 2007). It should be used 
during pregnancy only when the care provider and patient 
conclude that the beneﬁ  ts of the drug exceed the potential 
risks to the fetus. The CDC recommends that HIV-infected 
mothers should not breastfeed their infants to avoid risking 
postnatal exposure to HIV. It is not known whether lopinavir 
is secreted in human milk. In the US, where HIV-infected 
women are strongly discouraged from breastfeeding, this is 
of little relevance. In resource poor areas of the world, where 
breastfeeding is still the norm, the potential implications of 
neonatal exposure to the drug need to be considered.
Pediatric use
The safety, efficacy, and pharmacokinetic profiles of 
lopinavir/ritonavir in pediatric patients below the age of 
6 months have not been established. Once-daily dosing 
of lopinavir/ritonavir has, likewise, not been evaluated in 
pediatric patients. The recommended dosage in children 
is 100 mg/25 mg to 400 mg/100 mg twice daily based 
upon the body surface area or weight. Before prescribing 
lopinavir/ritonavir 100/25 mg tablets, children should be 
assessed for the ability to swallow intact tablets (Abbott 
Laboratories).Therapeutics and Clinical Risk Management 2008:4(5) 1026
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Use in the setting of hepatic and/or renal 
insufﬁ  ciency
Lopinavir is primarily metabolized by the liver, and drug 
concentrations may increase in hepatic impairment. Plasma 
protein binding is also decreased in hepatic impairment. 
Lopinavir/ritonavir should be used with caution in patients 
with signiﬁ  cant hepatic impairment. Patients with underlying 
hepatitis B or C or marked elevations in transaminase levels 
prior to treatment may be at increased risk for developing or 
worsening of transaminase elevations or hepatic decompen-
sation with use of lopinavir/ritonavir. Hepatitis C coinfection 
and baseline elevations of transaminases are associated with 
an increased risk of severe liver events (Gonzalez-Requena 
et al 2004; Palacios et al 2006). Lopinavir/ritonavir has 
very limited excretion through the kidneys, and renal insuf-
ﬁ  ciency has little impact on the pharmacokinetics of the drug 
(FDA/Center for Drug Evaluation and Research).
Use in the setting of other comorbidities
New onset diabetes mellitus, exacerbation of pre-existing 
diabetes mellitus, and hyperglycemia have been reported 
during post-marketing surveillance in HIV-1 infected patients 
receiving lopinavir/ritonavir therapy, but a causal relation-
ship has not been established (Abbott Laboratories). It may 
be prudent to exercise caution in the use of this drug in 
those with diabetes mellitus or glucose intolerance. Simi-
larly, hyperlipidemia is a relatively common consequence 
of lopinavir/ritonavir therapy, and this should be consid-
ered when therapeutic choices are made for patients with 
pre-existing lipid disorders.
Clinical trials
Lopinavir/ritonavir has been extensively studied for use in 
the management of HIV-infection in both treatment-naïve and 
treatment-experienced patients. According to the guidelines 
for the treatment of HIV infection by the US Department 
of Health and Human Services and British HIV Associa-
tion, lopinavir/ritonavir is one of the preferred PIs for use 
in the ﬁ  rst-line treatment regimens of HIV-infected adults 
and adolescents (Panel on clinical practices for treatment 
of HIV infection; Gazzard B on behalf of BHIVA Writing 
Committee). It is also a standard of care option in the 
International AIDS Society-USA Panel recommendations 
(Hammer et al 2006).
Treatment-naïve patients
Abbott 720 was a randomized blinded, multi-center trial 
evaluating treatment with lopinavir/ritonavir at 3 dose 
levels (200/100 mg twice daily, 400/100 mg twice daily, 
and 400/200 mg twice daily) together with stavudine (40 mg 
bid) and lamivudine (150 mg bid). All patients were switched 
to lopinavir/ritonavir 400/100 mg twice daily between 
weeks 48 and 72. Through 360 weeks of treatment, the 
proportion of patients with HIV-1 RNA   400 copies/mL and 
  50 copies/mL were 61% and 59% respectively (n = 100). 
Among patients completing 360 weeks of treatment with 
CD4+ cell count measurements (n = 60), the mean (median) 
increase in CD4+ lymphocyte count was 501 (457) cells/mm3 
above baseline. Thirty-nine patients (39%) discontinued the 
study, including 13 (13%) discontinuations due to adverse 
reactions and 1 (1%) death (Murphy et al 2001, 2008). This 
study established the antiviral efﬁ  cacy of lopinavir/ritonavir, 
and the extremely long follow-up provided evidence for the 
sustained effect of this agent over time.
In a randomized, double-blind, multicenter trial (n = 653) 
comparing lopinavir/ritonavir (400/100 mg twice daily) plus 
stavudine and lamivudine versus nelﬁ  navir (750 mg 3 times 
daily) plus stavudine and lamivudine, a signiﬁ  cantly larger 
proportion of patients treated with lopinavir/ritonavir than 
with nelﬁ  navir achieved the endpoints of  400 copies/mL 
of HIV RNA (75% vs 63%, p   0.001) and  50 copies/mL 
(67% vs 52%, p   0.001) (Walmsley et al 2002). None of 
the patients treated with lopinavir/ritonavir in this study 
developed HIV protease mutations, in contrast to 33% of 
those treated with nelﬁ  navir (p   0.001). Similar mean 
increases from baseline CD4+ lymphocyte counts to week 
48 were observed in the lopinavir/ritonavir group and the 
nelﬁ  navir group (207 and 195 cells/mm3, respectively). This 
study demonstrated the superiority of lopinavir/ritonavir 
over unboosted nelﬁ  navir, which was the previous standard 
of care.
An open-label, multicenter trial compared the efﬁ  cacy 
of lopinavir/ritonavir (800/200 mg) once daily plus 
tenofovir DF and emtricitabine versus lopinavir/ritonavir 
400/100 mg twice daily plus tenofovir DF and emtricitabine 
in 190 antiretroviral treatment naïve patients (Murphy et al 
2001) 71% of the patients treated with once daily lopinavir/
ritonavir achieved and maintained virologic suppression 
(VL   50 copies/mL) compared with 65% of the patients 
who were treated with a regimen of twice-daily lopinavir/
ritonavir. This study proved that once-daily dosing of 
lopinavir/ritonavir is therapeutically equivalent to twice-daily 
dosing in antiretroviral naïve subjects.
KLEAN (n = 878) was an open-label, randomized, non-
inferiority study that compared fosamprenavir-ritonavir with 
lopinavir-ritonavir, each in combination with a ﬁ  xed dose of Therapeutics and Clinical Risk Management 2008:4(5) 1027
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abacavir-lamivudine, for 48 weeks (Eron et al 2006). The 
antiviral and immunological responses in the fosamprenavir/
ritonavir group were similar to those in the lopinavir/ritonavir 
group with a similar tolerability and adverse effect proﬁ  le.
The GEMINI study evaluated the efﬁ  cacy and tolerability 
of saquinavir/ritonavir versus lopinavir/ritonavir each in 
combination with emtricitabine/tenoﬁ  vir as initial therapy 
in antiretroviral naïve patients over 48 weeks (Walmsley 
et al 2007). It was a prospective multicenter open labeled 
trial with 337 patients in 5 countries. At 48 weeks, patients 
treated with boosted saquinavir showed a similar viro-
logic response when compared to the patients treated with 
lopinavir/ritonavir with 64.7% and 63.5% of patients treated 
with saquinavir/ritonavir and lopinavir/ritonavir, respec-
tively, achieving VL   50 copies/mL. The CD4+ lymphocyte 
count response in the two groups was also comparable with a 
median increase from baseline of 178 for the patients treated 
with saquinavir/ritonavir and 204 for patients treated with 
lopinavir/ritonavir. The degree of lipid perturbation was 
higher in the lopinavir/ritonavir group than in the boosted 
saquinavir group.
The CASTLE trial compared boosted atazanavir and 
lopinavir/ritonavir in 883 antiretroviral naïve patients. The 
effect on viral suppression (HIV RNA   50) was similar 
at 48 weeks (78% vs 76% respectively). The mean CD4+ 
lymphocyte count increases from baseline were 203 cells/
mm3 in atazanavir/ritonavir-treated patients and 219 cells/
mm3 in patients who were treated with lopinavir/ritonavir. 
However, the patients treated with ritonavir boosted atazana-
vir demonstrated a lower incidence of gastrointestinal adverse 
events and hyperlipidemia (Molina et al 2008).
The ARTEMIS study was a randomized trial comparing 
once daily darunavir/ritonavir to once or twice daily 
lopinavir/ritonavir in 687 antiretroviral-naïve subjects. 
At 48 weeks, time-to-loss-of-virologic response analysis 
determined that 84% patients receiving darunavir and 
78% patients receiving lopinavir achieved HIV viral 
RNA   50 copies/mL thus proving the non-inferiority of 
darunavir/ritonavir. Lopinavir/ritonavir was found to have a 
less favorable safety proﬁ  le with a greater number of gastro-
intestinal-related adverse effects (Ortiz et al 2008).
A recent study completed by the AIDS Clinical Trials 
Group (ACTG), Study A5142, compared regimens of 
2 nucleoside/tide reverse transcriptase inhibitors (NRTIs) 
plus lopinavir ritonavir versus two NRTIs plus efavirenz, 
versus an NRTI-sparing regimen of efavirenz and lopinavir/
ritonavir in 757 antiretroviral-naïve subjects (Riddler et al 
2008). The authors found that, over 96 weeks of follow-up, 
virologic failure was signiﬁ  cantly less frequent in the two 
NRTI-efavirenz arm than in the two NRTI-lopinavir/ritonavir 
arm. Increases of CD4+ lymphocyte counts from baseline 
were signiﬁ  cantly higher in the two NRTI-lopinavir/ritonavir 
arm, and incidence of new drug resistance mutations was 
lower in the two NRTI-lopinavir/ritonavir arm. The NRTI-
sparing combination of efavirez and lopinavir/ritonavir 
produced rates of viral suppression similar to those of 
two NRTIs-efavirenz, but was associated with increased 
toxicity.
Treatment-experienced patients
Lopinavir/ritonavir has been extensively evaluated versus 
other protease inhibitors in patients who are antiretroviral 
therapy experienced after virological failure on previ-
ous regimens. An open-label, randomized, multicenter 
trial of lopinavir/ritonavir with nevirapine and nucleoside 
reverse transcriptase inhibitors versus investigator-selected 
protease inhibitor(s) plus nevirapine and nucleoside reverse 
transcriptase inhibitors in 288 single protease inhibitor-
experienced, non-nucleoside reverse transcriptase inhibitor 
(NNRTI)-naïve patients showed a greater proportion of 
patients with virologic suppression among those treated with 
lopinavir/ritonavir based regimens (57% vs 33%) (Pollard 
et al 2004).
A salvage trial of lopinavir/ritonavir combined with 
efavirenz in 57 patients who had failed at least two 
PI based regimens showed that virological response was 
correlated with the number of lopinavir mutations. Virologic 
suppression (HIV-RNA   400 copies/mL) was achieved in 
91% of patients with 0–5 mutations, 71% of the patients with 
6–7 mutations and only 33% of patients with 8–10 mutations 
(Kempf et al 2002). In PI and NNRTI-experienced patients 
lopinavir/ritonavir has been shown to produce a better 
virologic response than unboosted atazanavir (Cohen et al 
2005). Lopinavir/ritonavir was shown to be superior to 
unboosted atazanavir in a study comparing the two agents 
in 300 patients who had failed a previous PI-based regimen. 
Virologic suppression (HIV-RNA   50 copies/mL) was 
seen in 54% of those taking lopinavir/ritonavir versus 
38% of those taking unboosted atazanavir by intent to treat 
analysis (p = 0.008) (Cohen et al 2005). A randomized, 
non-blinded study (A5116) comparing combination therapy 
with lopinavir/ritonavir 533 mg/133 mg twice daily and 
efavirenz 600 mg once daily (in an NRTI-sparing regimen) 
with efavirenz and two NRTIs in patients (n = 236) who 
switched from PI or NNRTI-based regimens, showed that 
the combination of two NRTIs with efavirenz was more Therapeutics and Clinical Risk Management 2008:4(5) 1028
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effective in achieving virologic suppression. The lopinavir/
ritonavir-based regimen in this study had signiﬁ  cantly more 
toxicity-related discontinuations and shorter time to virologic 
failure (p = 0.001) (Fischl et al 2007). Lopinavir/ritonavir 
was one of the four PIs administered to patients in the 
RESIST (Randomized Evaluation Strategic Intervention 
in Multi-Drug Resistant Patients with Tipranavir) studies. 
An analysis of the patients treated with tipranavir/ritonavir 
vs lopinavir/ritonavir showed a better virologic response 
(HIV-1 VL reduction of  1 log10 from baseline) at 
24 weeks in patients receiving tipranavir/ritonavir (40%) 
versus lopinavir/ritonavir (21%) (Cahn et al 2006; Gathe 
et al 2006) At 48 weeks, tipranavir/ritonavir therapy showed 
an improved virologic and immunological response rate 
compared with lopinavir/ritonavir in patients with virus 
exhibiting reduced susceptibility to lopinavir/ritonavir 
(Walmsley et al 2007).
In a randomized controlled trial (TITAN) comparing 
darunavir/ritonavir with lopinavir/ritonavir in treatment 
experienced, lopinavir naïve patients (n = 595), at week 
48 a signiﬁ  cantly greater number of patients treated with 
darunavir/ritonavir had HIV RNA  400 copies/mL (77% vs 
68%). Fewer patients who were treated with darunavir/
ritonavir developed primary protease mutations or nucleoside 
analogue mutations as compared to lopinavir/ritonavir 
(Bongiovanni et al 2003).
The POWER 1 and 2 studies compared the safety and 
efﬁ  cacy of boosted darunavir with that of the available 
protease inhibitors including lopinavir/ritonavir in a group 
of 255 highly antiretroviral experienced subjects. A pooled 
analysis of the two studies showed that at 48 weeks, patients 
in POWER 1 and 2 on darunavir/ritonavir achieved superior 
virologic suppression and immunologic response when com-
pared with other currently available PIs including lopinavir/
ritonavir (Clotet et al 2007).
The MOTIVATE 1 and 2 studies showed that maraviroc, 
in combination with optimized background therapy (OBT), 
demonstrated superior virologic and immunologic treatment 
outcomes compared to OBT alone in treatment-experienced 
patients infected with CCR5-tropic HIV-1. A subanalysis of 
the MOTIVATE 1 and 2 studies showed that patients receiv-
ing maraviroc who had no lopinavir/ritonavir resistance, had 
an increased likelihood of achieving an undetectable viral 
load when lopinavir/ritonavir was included in the OBT (van 
der Ryst et al 2007). Lopinavir/ritonavir was also a part of 
the OBT in the BENCHMRK-1 and BENCHMRK-2 trials 
which were randomized double blind placebo controlled 
trials demonstrating the efﬁ  cacy of the integrase inhibitor 
raltegravir when used in treatment experienced HIV-infected 
subjects who had failed antiretroviral therapies, and who had 
HIV virus resistant to at least one drug in each of the three 
available classes of oral antiretroviral therapies (Grinsztejn 
et al 2007).
Monotherapy with lopinavir/ritonavir
It has been hypothesized that monotherapy with a 
ritonavir-boosted HIV protease inhibitor may offer protec-
tion from the long-term toxicities of NRTIs while effectively 
maintaining long-term virological suppression (Sax 2005). 
A retrospective study (n = 51) of virologically suppressed 
patients (HIV-RNA   50 copies/mL), who were switched 
to lopinavir/ritonavir monotherapy in an attempt to simplify 
treatment, found monotherapy with lopinavir/ritonavir to 
be a safe and effective treatment simpliﬁ  cation approach 
especially in patients who were virologically suppressed on 
combination regimens containing lopinavir/ritonavir (Molto 
et al 2007).
MONARCH was a prospective, randomized, open label 
trial comparing lopinavir/ritonavir monotherapy (n = 83) 
with a standard regimen of lopinavir/ritonavir along with 
zidovudine and lamivudine (n = 53) as an initial treatment in 
treatment-naive patients with HIV-RNA   100,000 copies/ml. 
Lopinavir/ritonavir monotherapy demonstrated lower rates of 
virological suppression compared with lopinavir/ritonavir-
NRTI therapy. At 48 weeks, in an intent-to-treat analysis, 
53 of 83 patients (64%) in the monotherapy group and 
40 of 53 patients (75%) in the triple-drug group achieved 
the primary virologic endpoint (p = 0.19). The on-treatment 
analysis indicated that 80 and 95% of patients reached the 
primary endpoint in the monotherapy and NRTI-lopinavir/
ritonavir, respectively (p   0.02) (Delfraissy et al 2008).
A randomized, open-label, non-inferiority clinical trial in 
205 virologically suppressed patients compared the continua-
tion of triple therapy with lopinavir/ritonavir and two NRTIs 
versus lopinavir/ritonavir monotherapy with reintroduction of 
two nucleosides if virologic failure occurred with lopinavir/
ritonavir monotherapy (Pulido et al 2008). At 48 weeks, 
94% of lopinavir/ritonavir monotherapy recipients survived 
without virologic failure compared with 90% of subjects 
receiving NRTI-lopinavir/ritonavir therapy. Episodes of 
low-level viremia were more common in patients receiving 
lopinavir/ritonavir monotherapy. In this study, 48 weeks 
of lopinavir/ritonavir monotherapy with reintroduction 
of nucleosides as needed was found to be non-inferior to 
continuation of two nucleosides and lopinavir/ritonavir in 
patients with prior stable suppression.Therapeutics and Clinical Risk Management 2008:4(5) 1029
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Pediatric studies
Lopinavir/ritonavir has been evaluated in HIV-infected 
children (n = 100) between 3 months and 12 years of age in 
an open-label multicenter trial. Patients were randomized 
to either 230 mg lopinavir/57.5 mg ritonavir/m2 or 
300 mg lopinavir/75 mg ritonavir/m2. Through 48 weeks 
of therapy, the proportion of patients who achieved and 
sustained an HIV-1 RNA   400 copies/mL was 80% for 
antiretroviral naïve patients and 71% for antiretroviral 
experienced patients. The mean CD4+ lymphocyte count 
increase from baseline was 404 cells/mm3 for antiretroviral 
naïve and 284 cells/mm3 for antiretroviral experienced 
patients treated through 48 weeks. The drug was well toler-
ated overall, and there were very few adverse events with 
possible or probable relationship to the drug. A rash was 
noticed in 2 children and 2 others interrupted therapy inter-
mittently due to elevations of amylase or hepatic enzymes. 
There were 2 premature discontinuations; 1 because of 
pancreatitis possibly related to lopinavir/ritonavir and the 
other due to an AIDS-associated malignancy (Saez-Llorens 
et al 2003).
Resistance
The pattern of resistance to lopinavir/ritonavir in 
antiretroviral therapy naïve patients has not been charac-
terized (Abbott Laboratories). No clinical resistance was 
described in a clinical trial of antiretroviral therapy naïve 
adult patients with HIV infection (King et al 2004). In 
another trial, sustained clinical efﬁ  cacy with no clinical 
resistance to lopinavir/ritonavir was observed in ART-naïve 
patients treated with lopinavir/ritonavir based regimens 
for up to 7 years (Murphy et al 2008). Similar results were 
seen in antiretroviral therapy naïve children who received 
lopinavir/ritonavir for 48 weeks (Saez-Llorens et al 2003). 
In a randomized double-blind trial of 653 antiretroviral 
therapy naïve patients who received lopinavir/ritonavir 
or nelﬁ  navir plus lamivudine and stavudine for up to 96 
weeks, no primary resistance mutations were seen in patients 
treated with lopinavir/ritonavir. In comparison, 45% of 
patients receiving nelﬁ  navir showed evidence of resistance 
(p   0.001) (King et al 2004). Resistance to lopinavir/
ritonavir has been shown to emerge in patients who have 
been exposed to other protease inhibitors. The mutations 
associated with decreased activity of lopinavir/ritonavir 
are 10/I/R/V, 20 M/R, 24U, 32I, 33F, 46I/L, 47V/A, 50V, 
53L, 54V/L/A/M/T/S, 63P, 71V/Y, 73S, 82A/FT/S, 84V, 
and 90M ( Kempf et al 2001). Lopinavir/ritonavir retains 
excellent antiviral efﬁ  cacy despite the presence of 5 or fewer 
primary PI resistance mutations, but decreased efﬁ  cacy is 
observed in the presence of higher numbers of mutations 
(Kempf et al 2002). The most common mutations associated 
with lopinavir resistance in antiretroviral therapy experi-
enced adults are 46I/L. Mutations 32I and 47A are associ-
ated with high level resistance (Johnson et al 2006). The 
incidence of cross-resistance between lopinavir/ritonavir 
and other protease inhibitors is low. However, cross resis-
tance between lopinavir/ritonavir and amprenavir may 
occur, and amprenavir resistance mutations may lead to 
decreased lopinavir/ritonavir effect. Mutations associated 
with lopinavir/ritonavir resistance are also associated with 
atazanavir resistance. In a study of dual PI therapy in a 
cohort of patients with an extensive pre-treatment history 
and highly variable pharmacokinetics, the absence of viral 
resistance mutations at V82T/A/F/I/S and 154M/V/L were 
highly predictive of therapeutic success with a regimen of 
saquinavir and lopinavir/ritonavir without reverse tran-
scriptase inhibitors (von Hentig et al 2007). Phenotypic 
results can be used to guide interpretation of resistance and 
cross-resistance to lopinavir/ritonavir (Paulsen et al 2002). 
Lopinavir/ritonavir’s high genetic barrier to genotypic resis-
tance is one factor contributing to the enhanced forgiveness 
of non-adherence that this agent exhibits in comparison to 
other PIs (Shuter et al 2007).
Drug interactions
Protease inhibitors including lopinavir/ritonavir are substrates 
for CYP3A4 and CYP3A5 isoenzymes and may also inhibit 
or induce the activity of CYP3A4. Lopinavir/ritonavir may 
have signiﬁ  cant interactions with drugs that are inducers 
or inhibitors of these enzymes and also with drugs that 
are substrates for the CYP3A4 and CYP3A5. Drugs that 
are contraindicated or require caution for coadministration 
with lopinavir/ritonavir are listed in Table 1. Interaction of 
lopinavir/ritonavir with other antiretroviral medications may 
require dosage adjustments. Table 2 summarizes the major 
interactions of lopinavir/ritonavir with other antiretroviral 
agents.
Adverse reactions
Lopinavir/ritonavir-containing antiretroviral regimens 
are generally well tolerated. The most frequent side 
effects reported are diarrhea, nausea, and vomiting. 
These gastrointestinal adverse effects are generally mild 
to moderate (Abbott Laboratories). Diarrhea related to 
lopinavir/ritonavir therapy is reported by 15%–25% of 
patients. The incidence of diarrhea is dose-related and, with Therapeutics and Clinical Risk Management 2008:4(5) 1030
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the old capsule formulation, occurred more frequently with 
the lopinavir/ritonavir 800/200 mg once-daily dose than 
lopinavir/ritonavir 400/100 mg twice-daily dose (Murphy 
et al 2001). The newer tablet formulation is better tolerated 
than the capsule formulation. The incidence of diarrhea due 
to lopinavir/ritonavir is higher than that due to atazanavir 
(Johnson et al 2005). However, patients who switched 
therapy from another PI-based regimen to lopinavir/
ritonavir based regimen showed an overall improvement 
in side effects and health related quality of life (Luo et al 
2004). Immune reconstitution syndrome has been reported 
in patients treated with antiretroviral regimens containing 
lopinavir/ritonavir, manifested as an inﬂ  ammatory response 
to indolent opportunistic infections. Serious side effects of 
lopinavir/ritonavir therapy are unusual. Pancreatitis has been 
seen rarely in patients on lopinavir/ritonavir therapy, and 
may have been related to marked elevations in triglyceride 
levels. Patients with a known history of pancreatitis are more 
likely to develop pancreatitis on lopinavir/ritonavir therapy 
(Oldﬁ  eld and Plosker 2006). Lopinavir/ritonavir can cause 
transient elevations in transaminase levels, but these are 
usually not clinically signiﬁ  cant. The incidence of severe 
hepatic events in patients receiving lopinavir/ritonavir is 
very low. Hepatitis C coinfection and baseline elevations 
in transaminases may be associated with severe liver 
events in lopinavir/ritonavir recipients (Palacios et al 
2006). Patients receiving lopinavir/ritonavir therapy with 
underlying liver disease should be monitored closely with 
frequent measures of hepatic function (Abbott Laborato-
ries). Like other members of the protease inhibitor class, 
lopinavir/ritonavir may cause signiﬁ  cant lipid elevations 
and fat redistribution. Hypertriglyceridemia (triglycerides 
 750 mg/dL) and hypercholesterolemia (total cholesterol 
 300 mg/dL) were the most frequently observed laboratory 
abnormalities in lopinavir/ritonavir recipients in clinical 
trials and may be the reason for discontinuation of therapy 
in some patients (Bongiovanni et al 2005). Increases in 
total cholesterol and triglycerides are seen within the ﬁ  rst 
month of starting therapy and are relatively stable after 
this time (Lafeuillade et al 2004). The lipid elevations due 
to lopinavir/ritonavir generally respond to lipid lowering 
therapy. Some trials have found that the lipid derangements 
Table 1 Drug interactions with co-administration with lopinavir/ritonavir
Rifampin Contraindicated – may lead to loss of virologic response and possible resistance to PIs 
and other antiretroviral agents
Rifabutin Dose of rifabutin should be reduced 75% of the maximal dose
Clarithromycin Dose of clarithromycin should be reduced in patients with renal insufﬁ  ciency
Metronidazole Disulﬁ  ram like reaction with lopinavir/ritonavir oral solution (contains 40% alcohol)
Ergot derivatives Contraindicated – acute ergot toxicity with vasospasm and ischemia of extremities 
and other tissues
Cisapride Contraindicated – cardiac arrhythmias
St. John’s Wort Contraindicated – may lead to loss of virologic response and possible resistance to PIs 
and other antiretroviral agents
Trazodone Increased levels of trazodone
Lovastatin, simvastatin Potential for myopathy including rhabdomyolysis
Pimozide Contraindicated – cardiac arrhythmias
Benzodiazepines Contraindicated – prolonged sedation and respiratory depression
Phenytoin Decreased AUC and Ctrough of both drugs
Methadone Dosage of methadone may need to be increased
Voriconazole Lack of data on co-administration
Fluconazole, ketoconazole Avoid high doses of these drugs with lopinavir/ritonavir
Fluticasone Cushing’s syndrome, adrenal suppression, osteoporosis
Amiodarone, lidocaine, quinidine Increased levels of these agents
Propafenone Contraindicated – cardiac arrhythmias
Flecainide Contraindicated – cardiac arrhythmias
PDE5 inhibitors (sidenaﬁ  l, tadaﬁ  l, vardenaﬁ  l) hypotension, syncope, priapism and visual changes
Warfarin May require more frequent monitoring of INR and dosage adjustments of warfarin ritonavir
Abbreviations: INR, international normalized ratio; PI, HIV-1 protease inhibitor.Therapeutics and Clinical Risk Management 2008:4(5) 1031
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caused by lopinavir/ritonavir were more severe than those 
caused by other PIs such as atazanavir, atazanavir/ritonavir, 
or nelﬁ  navir (Walmsley et al 2002; Cohen et al 2005), but 
other trials reported similar elevations in triglycerides and 
cholesterol in lopinavir/ritonavir recipients as compared 
to subjects receiving other PIs (Dragsted et al 2005). PIs 
including lopinavir/ritonavir have been associated with 
insulin resistance, new onset diabetes, and worsening of 
pre-existing diabetes requiring hypoglycemic agents in some 
patients. Hyperglycemia may persist in patients even after 
discontinuation of lopinavir/ritonavir. Fat redistribution 
including central obesity, dorsocervical fat enlargement 
(buffalo hump), peripheral wasting, facial wasting, breast 
enlargement, and cushingoid appearance have been observed 
in patients receiving antiretroviral therapy including 
lopinavir/ritonavir. However, a causal relationship has not 
been established (Abbott Laboratories). There is evidence 
to suggest that fat redistribution in less likely to occur in 
individuals receiving unboosted atazanavir (Haerter et al 
2004). Less common adverse effects of lopinavir/ritonavir 
therapy include allergic reaction, asthenia, malaise, head-
ache, myalgias, arthralgias, myocardial infarction, seizures, 
and lactic acidosis.
Conclusion
Lopinavir/ritonavir played a major role in ushering in the era 
of boosted PI therapy, and in offering the ﬁ  rst good option 
to patients who had failed prior therapy. It has proven efﬁ  ca-
cious in the treatment of HIV infection in both ART naive 
as well as experienced patients. Despite the availability 
of newer agents, the wealth of clinical experience with 
this important medication ensures it a prominent place 
in the antiretroviral treatment armamentarium for years 
to come.
Table 2 Drug interactions of lopinavir/ritonavir with other antiretroviral agents
Drug class, agents Drug interaction Clinical signiﬁ  cance
NNRTIs
Efavirenz ↓ lopinavir concentration Increased dose of lopinavir/ritonavir may be needed
Lopinavir/ritonavir should not be used once daily with efavirenz
Nevirapine ↓ lopinavir concentration Increased dose of lopinavir/ritonavir may be needed
Lopinavir/ritonavir should not be used once daily with nevirapine
Delavirdine ↑ lopinavir concentration Dose not established for use in combination
NRTIs
Abacavir ↓ abacavir concentration Unknown
Tenofovir ↑ tenofovir concentration Monitor for adverse reactions of tenofovir
Zidovudine ↓ zidovudine concentration Unknown
PIs
Amprenavir ↓ lopinavir concentration
↑ amprenavir concentration
Lopinavir/ritonavir should not be administered in once-daily 
combination with amprenavir
Fosamprenavir/ritonavir ↓ lopinavir concentration
↓ amprenavir concentration
Increased rate of adverse effects observed
Appropriate dose in combination not established
Indinavir ↑ indinavir concentration Decrease indinavir dose to 600 bid when used with 
lopinavir/ritonavir 400/100 mg bid
Once-daily lopinavir/ritonavir has not been studied with indinavir
Nelﬁ  navir ↓ lopinavir concentration
↑ nelﬁ  navir concentration
↑ M8 metabolite of nelﬁ  navir
Lopinavir/ritonavir should not be used once daily in combination 
with nelﬁ  navir
Ritonavir ↑ lopinavir concentration Appropriate doses of additional ritonavir not established
Saquinavir ↑ saquinavir concentration Saquinavir dose should be 1000 mg bid with lopinavir/ritonavir 
400/100 mg bid
Lopinavir/ritonavir once daily has not been studied 
with saquinavir
Tipranavir ↓ lopinavir AUC and Cmin Lopinavir/ritonavir should not be used with tipranavir 500 mg 
bid/ritonavir 200 mg bid
Abbreviations: NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, HIV-1 protease inhibitor.Therapeutics and Clinical Risk Management 2008:4(5) 1032
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